Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
40.2M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
4.36M
-
Shares change
-
-762K
-
Total reported value, excl. options
-
$8.17M
-
Value change
-
-$1.26M
-
Put/Call ratio
-
0.67
-
Number of buys
-
7
-
Number of sells
-
-9
-
Price
-
$1.88
Significant Holders of Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) as of Q4 2023
35 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.36M shares
of 40.2M outstanding shares and own 10.83% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.69M shares), VANGUARD GROUP INC (428K shares), Boxer Capital, LLC (209K shares), BAKER BROS. ADVISORS LP (200K shares), Ikarian Capital, LLC (189K shares), Privium Fund Management (UK) Ltd (120K shares), RENAISSANCE TECHNOLOGIES LLC (113K shares), GEODE CAPITAL MANAGEMENT, LLC (78.5K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (64K shares), and CITADEL ADVISORS LLC (38K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.